Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaoling Li
Institution:
Liaoning Cancer Hospital & Institute
Observed institutions:
Liaoning Cancer Hospital & Institute,
China Medical University
ORCID:
0000-0002-5163-8413
Observed ORCID:
0000-0002-5163-8413
OpenAlex ID:
A5090263356
A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study
2024
·
Meiting Chen
, Lu Li
, et al.
·
Cancer
·
19
PDF
Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies
2022
·
Shuchen Chen
, Honglin Zhu
, et al.
·
Cancer Medicine
·
6
PDF
Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non‐small cell lung cancer
2022
·
Shuchen Chen
, Wanyi Huang
, et al.
·
Cancer Medicine
·
5
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer
2025
·
Shun Lu
, Yongfeng Yu
, et al.
·
Translational Lung Cancer Research
·
4
Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study
2025
·
Yuan Yang
, Ping Yang
, et al.
·
Annals of Medicine
·
3
Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study
2026
·
Li Wang
, Keshu Zhou
, et al.
·
HemaSphere
PDF
Safety and effectiveness of fuzuloparib in patients with ovarian cancer: A nationwide, multicenter, prospective real-world study.
2025
·
Qinglei Gao
, Jie Jiang
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
7
Citation count:
37
H-index:
4
I10-index:
1
Year
Topic
Type